secwatch / observer
8-K filed November 18, 2024, 6:59 PM ET ticker SYRE CIK 0001636282
other material confidence high sentiment negative materiality 0.85

Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls

Spyre Therapeutics, Inc.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001636282-24-000105
form_type
8-K
ticker
SYRE
cik
0001636282
company_name
Spyre Therapeutics, Inc.
filed_at
2024-11-18T23:59:59+00:00
discovered_at
2026-05-14T18:03:09.058112+00:00
generated_at
2026-05-29T23:04:02.340991+00:00
sec_items
["4.02", "8.01"]
event_type
other_material
sentiment
negative
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001636282-24-000105
json_url
https://secwatch.observer/filing/0001636282-24-000105.json
markdown_url
https://secwatch.observer/filing/0001636282-24-000105.md
text_url
https://secwatch.observer/filing/0001636282-24-000105.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1636282/000163628224000105/0001636282-24-000105-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1636282/000163628224000105/syre-20241118.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Comparable filings

PLUR

Pluri gets EIB nod for loan talks; no enforcement until July 3 on €20M maturing today

Pluri Inc. June 1, 2026, 4:06 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

CORNER GROWTH ACQUISITION CORP. 2

Corner Growth Acquisition Corp. 2 to liquidate and dissolve after failing to complete business combination

CORNER GROWTH ACQUISITION CORP. 2 June 1, 2026, 4:00 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

Corner Growth Acquisition Corp.

Corner Growth Acquisition Corp. to liquidate; will redeem public shares

Corner Growth Acquisition Corp. June 1, 2026, 4:00 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

GPRO

GoPro refiles financials with going-concern warning; potential defaults on debt

GoPro, Inc. June 1, 2026, 9:12 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

STSS

Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South

Sharps Technology Inc. June 1, 2026, 8:15 AM ET other_material Items 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR
accession 0001636282-24-000105

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.